FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3010932917> ?p ?o ?g. }

• W3010932917 endingPage "108" @default.
• W3010932917 startingPage "1" @default.
• W3010932917 abstract "Background Most patients presenting with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) in primary care are prescribed antibiotics, but these may not be beneficial, and they can cause side effects and increase the risk of subsequent resistant infections. Point-of-care tests (POCTs) could safely reduce inappropriate antibiotic prescribing and antimicrobial resistance. Objective To determine whether or not the use of a C-reactive protein (CRP) POCT to guide prescribing decisions for AECOPD reduces antibiotic consumption without having a negative impact on chronic obstructive pulmonary disease (COPD) health status and is cost-effective. Design A multicentre, parallel-arm, randomised controlled open trial with an embedded process, and a health economic evaluation. Setting General practices in Wales and England. A UK NHS perspective was used for the economic analysis. Participants Adults (aged ≥ 40 years) with a primary care diagnosis of COPD, presenting with an AECOPD (with at least one of increased dyspnoea, increased sputum volume and increased sputum purulence) of between 24 hours’ and 21 days’ duration. Intervention CRP POCTs to guide antibiotic prescribing decisions for AECOPD, compared with usual care (no CRP POCT), using remote online randomisation. Main outcome measures Patient-reported antibiotic consumption for AECOPD within 4 weeks post randomisation and COPD health status as measured with the Clinical COPD Questionnaire (CCQ) at 2 weeks. For the economic evaluation, patient-reported resource use and the EuroQol-5 Dimensions were included. Results In total, 653 participants were randomised from 86 general practices. Three withdrew consent and one was randomised in error, leaving 324 participants in the usual-care arm and 325 participants in the CRP POCT arm. Antibiotics were consumed for AECOPD by 212 out of 274 participants (77.4%) and 150 out of 263 participants (57.0%) in the usual-care and CRP POCT arm, respectively [adjusted odds ratio 0.31, 95% confidence interval (CI) 0.20 to 0.47]. The CCQ analysis comprised 282 and 281 participants in the usual-care and CRP POCT arms, respectively, and the adjusted mean CCQ score difference at 2 weeks was 0.19 points (two-sided 90% CI –0.33 to –0.05 points). The upper limit of the CI did not contain the prespecified non-inferiority margin of 0.3. The total cost from a NHS perspective at 4 weeks was £17.59 per patient higher in the CRP POCT arm (95% CI –£34.80 to £69.98; p = 0.408). The mean incremental cost-effectiveness ratios were £222 per 1% reduction in antibiotic consumption compared with usual care at 4 weeks and £15,251 per quality-adjusted life-year gained at 6 months with no significant changes in sensitivity analyses. Patients and clinicians were generally supportive of including CRP POCT in the assessment of AECOPD. Conclusions A CRP POCT diagnostic strategy achieved meaningful reductions in patient-reported antibiotic consumption without impairing COPD health status or increasing costs. There were no associated harms and both patients and clinicians valued the diagnostic strategy. Future work Implementation studies that also build on our qualitative findings could help determine the effect of this intervention over the longer term. Trial registration Current Controlled Trials ISRCTN24346473. Funding This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in Health Technology Assessment ; Vol. 24, No. 15. See the NIHR Journals Library website for further project information." @default.
• W3010932917 created "2020-03-23" @default.
• W3010932917 creator A5002227290 @default.
• W3010932917 creator A5005801305 @default.
• W3010932917 creator A5006274396 @default.
• W3010932917 creator A5011449104 @default.
• W3010932917 creator A5024033890 @default.
• W3010932917 creator A5025881013 @default.
• W3010932917 creator A5026184110 @default.
• W3010932917 creator A5029702578 @default.
• W3010932917 creator A5030136605 @default.
• W3010932917 creator A5031526787 @default.
• W3010932917 creator A5039258652 @default.
• W3010932917 creator A5047237224 @default.
• W3010932917 creator A5052071674 @default.
• W3010932917 creator A5056500139 @default.
• W3010932917 creator A5058223988 @default.
• W3010932917 creator A5068567085 @default.
• W3010932917 creator A5070432856 @default.
• W3010932917 creator A5079149152 @default.
• W3010932917 creator A5082988150 @default.
• W3010932917 creator A5086247686 @default.
• W3010932917 creator A5087936641 @default.
• W3010932917 creator A5088754559 @default.
• W3010932917 date "2020-03-01" @default.
• W3010932917 modified "2023-10-01" @default.
• W3010932917 title "C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT" @default.
• W3010932917 cites W1791978714 @default.
• W3010932917 cites W1903571595 @default.
• W3010932917 cites W1976770755 @default.
• W3010932917 cites W1979891829 @default.
• W3010932917 cites W1982816514 @default.
• W3010932917 cites W1983561188 @default.
• W3010932917 cites W1986748536 @default.
• W3010932917 cites W1990166011 @default.
• W3010932917 cites W1999983855 @default.
• W3010932917 cites W2002726093 @default.
• W3010932917 cites W2012519534 @default.
• W3010932917 cites W2012556907 @default.
• W3010932917 cites W2021465218 @default.
• W3010932917 cites W2023886798 @default.
• W3010932917 cites W2034781418 @default.
• W3010932917 cites W2044903647 @default.
• W3010932917 cites W2057986787 @default.
• W3010932917 cites W2059469444 @default.
• W3010932917 cites W2070910851 @default.
• W3010932917 cites W2071686284 @default.
• W3010932917 cites W2082538594 @default.
• W3010932917 cites W2085001923 @default.
• W3010932917 cites W2089165963 @default.
• W3010932917 cites W2105283001 @default.
• W3010932917 cites W2106540827 @default.
• W3010932917 cites W2110282182 @default.
• W3010932917 cites W2110947112 @default.
• W3010932917 cites W2112692443 @default.
• W3010932917 cites W2113157074 @default.
• W3010932917 cites W2113709646 @default.
• W3010932917 cites W2118502261 @default.
• W3010932917 cites W2119679249 @default.
• W3010932917 cites W2120277552 @default.
• W3010932917 cites W2122147693 @default.
• W3010932917 cites W2123605512 @default.
• W3010932917 cites W2123964203 @default.
• W3010932917 cites W2124038714 @default.
• W3010932917 cites W2125522165 @default.
• W3010932917 cites W2128453617 @default.
• W3010932917 cites W2128659393 @default.
• W3010932917 cites W2129660502 @default.
• W3010932917 cites W2131681584 @default.
• W3010932917 cites W2133175028 @default.
• W3010932917 cites W2135165791 @default.
• W3010932917 cites W2142107643 @default.
• W3010932917 cites W2144400988 @default.
• W3010932917 cites W2144916541 @default.
• W3010932917 cites W2145334510 @default.
• W3010932917 cites W2146976869 @default.
• W3010932917 cites W2148673286 @default.
• W3010932917 cites W2151182129 @default.
• W3010932917 cites W2152702795 @default.
• W3010932917 cites W2153715784 @default.
• W3010932917 cites W2154729726 @default.
• W3010932917 cites W2156523739 @default.
• W3010932917 cites W2156949070 @default.
• W3010932917 cites W2158264979 @default.
• W3010932917 cites W2158270692 @default.
• W3010932917 cites W2159887611 @default.
• W3010932917 cites W2160477976 @default.
• W3010932917 cites W2160756794 @default.
• W3010932917 cites W2163267243 @default.
• W3010932917 cites W2166531344 @default.
• W3010932917 cites W2166907962 @default.
• W3010932917 cites W2167544636 @default.
• W3010932917 cites W2172218385 @default.
• W3010932917 cites W2289103858 @default.
• W3010932917 cites W2320150092 @default.
• W3010932917 cites W2473786944 @default.
• W3010932917 cites W2557094526 @default.
• W3010932917 cites W2582690631 @default.

• next